Compare · MAZE vs MRNA
MAZE vs MRNA
Side-by-side comparison of Maze Therapeutics Inc. (MAZE) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MAZE and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $56.02B, about 38.2x MAZE ($1.46B).
- Over the past year, MAZE is up 51.2% and MRNA is up 462.9% - MRNA leads by 411.7 points.
- MRNA has been more active in the news (20 items in the past 4 weeks vs 15 for MAZE).
- MRNA has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- Maze Therapeutics Inc.
- Moderna Inc.
- Price
- $24.60-6.71%
- $137.69-1.80%
- Market cap
- $1.46B
- $56.02B
- 1M return
- -8.96%
- +130.17%
- 1Y return
- +51.17%
- +462.92%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2018
- News (4w)
- 15
- 20
- Recent ratings
- 7
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MAZE
- President, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- GC and Corp. Secretary Courtney Phillips converted options into 11,000 shares (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $906,999 worth of shares (34,501 units at $26.29) as part of a pre-agreed trading plan and converted options into 50,000 shares (SEC Form 4)
- CSBO Dandekar Atul converted options into 12,500 shares, increasing direct ownership by 48% to 38,750 units (SEC Form 4)
- President, R&D & CMO Bernstein Harold exercised 36,141 shares at a strike of $4.65 and sold $425,512 worth of shares (16,141 units at $26.36) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- SEC Form 144 filed by Maze Therapeutics Inc.
- Maze Therapeutics to Participate in Three Upcoming Investor Conferences
- SEC Form 144 filed by Maze Therapeutics Inc.
- CSBO Dandekar Atul sold $206,824 worth of shares (7,500 units at $27.58) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $10.42 (SEC Form 4)
Latest MRNA
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax